

Serial No.: PCT/EP 97/02102 (22 April 1997)

Atty. Docket No.: 10496/P63132US0

---

4. (Amended) A process for the preparation of the peptide according to claim 1 and/or its pharmacologically active fragments [according to claim 2], characterized in that it is isolated from human blood using chromatographic methods.

5. (Amended) A process for the preparation of the peptide or its derivatives according to claim 1 and/or its pharmacologically active fragments [according to claim 2], characterized in that said peptide or its derivatives or fragments are prepared from the amino acids contained in the stated sequence in protected form by common methods of solid-phase and liquid-phase synthesis, deprotected and purified by per se known chromatographical methods.

6. (Amended) Medicaments containing the peptide according to claim 1 or its pharmacologically active fragments [according to claim 2] as the active ingredient in addition to usual excipients and additives.

---

8. (Amended) Antibodies obtainable by immunizing animals with the peptide according to claim 1 and/or its pharmacologically active fragments [according to claim 2], and/or by using hybridoma technology.

---

10. A method for the treatment of patients in need of an inhibition of HF-COLL-18/514cf or its derivatives [or fragments] according to claim 1 [or 2] or its pharmacologically active fragments by the administration of therapeutic amounts of an antagonist/inhibitor of HF-COLL-18/514cf.

11. (Amended) Use of the medicaments according to [claims] claim 6 [or 7] for the treatment of diseases of the human organism, especially in connection with capillary proliferations.

12. (Amended) Use of the medicaments according to [claims] claim 6 [or 7] for the treatment of diseases of the human organism, especially carcinoses.

13. (Amended) Use of the medicaments according to [claims] claim 6 [or 7] for the treatment of diseases of the human organism, especially involving the cardiovascular and nervous systems.

14. (Amended) Use of the medicaments according to [claims] claim 6 [or 7] for the treatment of diseases of the human organism, especially involving the [intugement] integument and the sense organs, especially the eyes.

15. (Amended) Use of the peptide or its derivatives according to claim 1, [the] its pharmacologically active fragments [according to claim 2 or the antibody according to claim 8], or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology for the preparation of a medicament for the treatment of disorders in inflammatory processes, disturbed inflammatory reactions, proliferation and maturation disorders of the blood-forming system.

16. (Amended) Use of the medicaments according to [claims] claim 6 [or 7 or the antibody according to claim 8] or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology for the treatment of systemic diseases in an overproduction or deficiency of HF-COLL-18/514cf, especially when, e.g., antibodies have been formed against it in former applications, or the use of HF-COLL-18/514cf in substitution therapy.

17. (Amended) Use of the medicaments according to [claims] claim 6 [or 7] for the treatment of chronic diseases[, partially accompanied by the diseases

---

mentioned in claims 11 to 16,] by using it in a suitable form for the treatment due to electrolytic activity in tumor and vascular diseases.

18. (Amended) Use of the medicaments according to [claims] claim 6 [or 7 or the antibody according to claim 8] or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology for the treatment of acute diseases [as mentioned in claims 11 to 16] by using it in a suitable form for the treatment of these diseases in intensive care.

19. (Amended) Use of the medicaments according to [claims] claim 6 [or 7 of the antibody according to claim 8] or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology for the diagnosis of diseases[, especially those mentioned in any of claims 11 to 16,] by preparing specific antibodies against synthetic fragments or the whole peptide or its derivatives and fragments and measuring the blood concentration of HF-COLL-18/514cf by immunoassays.